Alx Oncology Holdings Inc (NASDAQ: ALXO) kicked off on Tuesday, down -5.17% from the previous trading day, before settling in for the closing price of $1.74. Over the past 52 weeks, ALXO has traded in a range of $1.19-$17.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -43.84% over the past five years. While this was happening, its average annual earnings per share was recorded 26.31%. With a float of $30.92 million, this company’s outstanding shares have now reached $52.74 million.
Let’s look at the performance matrix of the company that is accounted for 72 employees. In terms of profitability, gross margin is 74.15%, operating margin of -6446.65%, and the pretax margin is -6095.12%.
Alx Oncology Holdings Inc (ALXO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Alx Oncology Holdings Inc is 41.38%, while institutional ownership is 55.64%. The most recent insider transaction that took place on Jan 06 ’25, was worth 3,998. In this transaction Interim CFO of this company sold 2,221 shares at a rate of $1.80, taking the stock ownership to the 87,902 shares. Before that another transaction happened on Dec 30 ’24, when Company’s Interim CFO sold 1,426 for $1.58, making the entire transaction worth $2,253. This insider now owns 90,123 shares in total.
Alx Oncology Holdings Inc (ALXO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.31% per share during the next fiscal year.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Take a look at Alx Oncology Holdings Inc’s (ALXO) current performance indicators. Last quarter, stock had a quick ratio of 4.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.50 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
Alx Oncology Holdings Inc (NASDAQ: ALXO) saw its 5-day average volume 0.7 million, a negative change from its year-to-date volume of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 39.47%. Additionally, its Average True Range was 0.17.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 33.33%, which indicates a significant increase from 27.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.48% in the past 14 days, which was lower than the 95.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5728, while its 200-day Moving Average is $5.4949. Nevertheless, the first resistance level for the watch stands at $1.7566 in the near term. At $1.8633, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9265. If the price goes on to break the first support level at $1.5867, it is likely to go to the next support level at $1.5235. Assuming the price breaks the second support level, the third support level stands at $1.4168.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
The company with the Market Capitalisation of 87.03 million has total of 52,743K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -160,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -30,710 K.
